Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?
- M. DediuAffiliated withMedical Oncology Department, Institute of Oncology Bucharest Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Adjuvant chemotherapy is established as a standard of care for resectable non-small cell lung cancer. However, this indication remains controversial for the stage IB as the results of the randomized trials and meta-analysis are obscuring on this issue. Moreover, the updated international guidelines do not prescribe the regular use of this strategy in stage IB. The aim of this paper is to review the current evidences regarding the benefit of adjuvant CT in this setting, and to provide clinical hints, which can lend a helping hand to the clinicians and their patients to take the right decision in this particular scenario.
KeywordsAdjuvant chemotherapy Stage IB Risk factors NSCLC
- Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?
memo - Magazine of European Medical Oncology
Volume 1, Issue 2 , pp 61-65
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Adjuvant chemotherapy
- Stage IB
- Risk factors
- Industry Sectors
- M. Dediu (A1)
- Author Affiliations
- A1. Medical Oncology Department, Institute of Oncology Bucharest, Bucharest, Romania